Mosunetuzumab for adults with relapsed/refractory follicular lymphoma after at least two prior therapies (compassionate use)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, multicenter observational review of medical records from patients with relapsed/refractory follicular lymphoma who received mosunetuzumab through a compassionate use program, led by IRCCS Ospedale San Raffaele in Milan. The analysis focuses on adults who had at least two prior lines of therapy and provided consent for use of their clinical data. Investigators will extract response rates, duration of response, progression-free survival estimates, and recorded adverse events from routine care documentation. No new treatments or visits are required for participants because the work analyzes existing clinical data to describe real-world outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (\>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two lines of therapy, treated with mosunetuzumab under a compassionate use program.
* Patients who have signed informed consent for treatment.

Exclusion Criteria:

* Age \<18 years
* Patients with other types of cancer/lymphoma
* Patients not eligible for the Mosunetuzumab compassionate use program

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Andres JM Ferreri, Prof
• Email: ferreri.clinicaltrials@hsr.it
• Phone: 0226439396

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mosunetuzumab for people with systemic lupus erythematosus

  This study tests mosunetuzumab in people with systemic lupus erythematosus, with or without active lupus nephritis.

  Recruiting at 24 sites Phase 2 Hoffmann-La Roche · CABA, Buenos Aires and 23 other locations · NCT07598396

• Phase 2 test of mosunetuzumab for CLL patients with detectable MRD

  This study tests whether adding mosunetuzumab to ongoing BTKi therapy can eliminate detectable minimal residual disease in adults with chronic lymphocytic leukemia who still have MRD after BTKi treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07566364

• Mosunetuzumab and Zeprumetostat in Follicular Lymphoma

  This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07555470

• Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma

  This trial tests whether adding the PD‑1 blocker tislelizumab to zanubrutinib, rituximab, and lenalidomide helps adults with relapsed or refractory follicular lymphoma who have had at least two prior therapies.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07418190

• Mosunetuzumab by subcutaneous injection as first-line therapy for low tumor burden follicular lymphoma

  This trial tests whether subcutaneous mosunetuzumab can be safely and effectively used as initial treatment for adults with newly diagnosed follicular lymphoma with low tumor burden.

  Recruiting at 4 sites Phase 2 Tel-Aviv Sourasky Medical Center · Haifa and 3 other locations · NCT07191249

• Mosunetuzumab to clear minimal residual disease in CLL and SLL.

  This trial will try mosunetuzumab, alone or with a BTK inhibitor, to clear minimal residual disease in people with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07052695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.